Encompass Health sees $18.5M of insider sales, CEO unloads $16.8M in 2026

Over the last year Encompass Health (EHC) has seen no insider purchases and eleven sales totaling $18,523,085, driving the buy‑sell ratio to 0.0×, a clear breach of the <0.2× heavy‑selling threshold. While insider selling can stem from routine equity‑compensation events, the concentration of value in a single executive and the timing of the trades merit closer scrutiny.

The most material transaction occurred on February 11, 2026 when CEO Mark J. Tarr sold 87,745 shares for $9,923,082. That same day he off‑loaded three additional blocks—16,216 shares for $1,751,814, 15,584 shares for $1,715,331, and 13,231 shares for $1,439,533—bringing his total proceeds on the date to $14,829,760. Across the 12‑month window the CEO’s seven sales summed to $16,746,688, representing 90.4% of all insider‑sale value. The remaining $1,776,397 came from the COO’s three sales ($499,138) and a single VP/SVP/EVP sale ($1,277,259) by Edmund Fay on March 9, 2026.

The monthly timeline highlights two spikes that stand out. In May 2025 insiders sold $14,886,126, and in February 2026 sales surged to $17,048,455, the latter driven almost entirely by the CEO’s quartet of trades. Both months exceed the $1 million activity threshold that signals material insider involvement, and each cluster involved multiple insiders within a 30‑day window, satisfying the “cluster selling” condition often interpreted as a coordinated signal.

From a market perspective EHC is trading at $106.08, down 0.52% on the day, with a 52‑week range position at 39% and an RSI of 62, indicating modest upward momentum but no extreme overbought condition. The stock’s YTD return of +0.7% is flat, suggesting that the recent insider sell pressure has not yet translated into a pronounced price decline. However, the sheer volume of sales—especially from the CEO—could be read by investors as a reduction in personal confidence, a factor that historically precedes periods of earnings volatility for healthcare service firms.

It is also worth noting that the COO’s three sales, while modest at $499,138, occurred in August 2024 ($126,062) and February 2026 ($373,076), aligning with the CEO’s larger sell windows. The VP’s single sale of $1,277,259 in March 2026 adds a third C‑suite participant to the pattern, reinforcing the perception of a coordinated liquidity event rather than isolated compensation exercises.

In sum, the data paints a picture of aggressive insider divestiture concentrated among the top three executives, a buy‑sell ratio that signals heavy selling, and clustered transactions that exceed material‑activity thresholds. While routine compensation cannot be ruled out, the magnitude and timing of the sales provide a bearish signal that market participants should weigh against the company’s operational outlook and upcoming earnings releases.